Related Experiment Video
Updated: May 23, 2026
06:20
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Measure What Matters: Rethinking Surrogate Metrics of Success in Radiation Oncology.
Lohith Satish1, Joshua Asper2, Mark Bonnen2
1UT Health San Antonio MD Anderson Cancer Center; UIWSOM.
Summary
Traditional radiation oncology metrics are outdated. New treatment starts are the best measure of departmental performance and financial value in modern radiotherapy, improving resource allocation.
Area of Science:
- Radiation Oncology
- Health Services Research
- Health Economics
Background:
- Traditional radiation oncology performance metrics (e.g., patients on treatment, fractions delivered) may not reflect current practices like hypofractionation and stereotactic radiotherapy.
- Modern radiotherapy involves complex treatment modalities and fractionation schedules, necessitating updated performance assessment tools.
Purpose of the Study:
- To analyze longitudinal trends in radiation oncology clinical operations and financial performance over a ten-year period.
- To identify value-based departmental performance metrics that better capture the complexities of contemporary radiotherapy.
Main Methods:
- Retrospective analysis of operational and financial data from FY15-24 at an NCI-designated cancer center.
- Extracted data included consultations, treatment starts, fractions, and collections from EMR and billing systems.
- Descriptive statistics assessed associations between operational surrogates and financial outcomes.
Main Results:
- Advanced modalities (IMRT, SBRT, SRS) utilization increased, with stereotactic courses rising from 4% to 22%.
- Average fractions per patient decreased, and the consultation-to-treatment start conversion rate dropped.
- New treatment starts showed the strongest correlation with financial collections (r=0.90), outperforming other census-based metrics.
Conclusions:
- Legacy metrics are inadequate for assessing contemporary radiation oncology performance.
- New treatment starts are a reliable surrogate for clinical throughput, financial performance, and physician workload.
- Benchmarking based on new treatment starts can enhance performance assessment and resource allocation in value-based care.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...